Terms: = Skin cancer AND FLT3, STK1, 2322, ENSG00000122025, P36888, FLK2, CD135, RP11-153M24_3 AND Prognosis
3677 results:
1. Identification of an anoikis-related gene signature and characterization of immune infiltration in skin cutaneous melanoma.
Xu Z; Huang J; Shi W; Qi Y; Yuan F; Lin B
Medicine (Baltimore); 2024 Apr; 103(17):e37900. PubMed ID: 38669429
[TBL] [Abstract] [Full Text] [Related]
2. Identification of prognostic m6A modification patterns and score system in melanoma patients.
Wang F; Chen P; Ouyang S; Xiong K; Liu Z; Wang Y
Medicine (Baltimore); 2024 Apr; 103(17):e37950. PubMed ID: 38669381
[TBL] [Abstract] [Full Text] [Related]
3. The Level of Agreement between Self-Assessments and Examiner Assessments of Melanocytic Nevus Counts: Findings from an Evaluation of 4548 Double Assessments.
Gefeller O; Kaiser I; Brockmann EM; Uter W; Pfahlberg AB
Curr Oncol; 2024 Apr; 31(4):2221-2232. PubMed ID: 38668067
[TBL] [Abstract] [Full Text] [Related]
4. Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors.
Nishimura T; Fujimoto H; Fujiwara T; Ito K; Fujiwara A; Yuda H; Itani H; Naito M; Kodama S; Furuhashi K; Yagi A; Saiki H; Yasuma T; Okano T; Tomaru A; Tanigawa M; Yoshida M; Hataji O; Ibata H; D'Alessandro-Gabazza CN; Gabazza EC; Kobayashi T
Cancer Med; 2024 Apr; 13(8):e7188. PubMed ID: 38629295
[TBL] [Abstract] [Full Text] [Related]
5. Could the mitotic count improve personalized prognosis in melanoma patients?
Buja A; Rugge M; Cozzolino C; Dossi F; Zorzi M; Vecchiato A; de Luca G; Del Fiore P; Tropea S; dall'Olmo L; Rossi CR; Boccuzzo G; Mocellin S
PLoS One; 2024; 19(4):e0302309. PubMed ID: 38626072
[TBL] [Abstract] [Full Text] [Related]
6. A chest CT-based nomogram for predicting survival in acute myeloid leukemia.
Yi X; Zhan H; Lyu J; Du J; Dai M; Zhao M; Zhang Y; Zhou C; Xu X; Fan Y; Li L; Dong B; Jiang X; Xiao Z; Zhou J; Zhao M; Zhang J; Fu Y; Chen T; Xu Y; Tian J; Liu Q; Zeng H
BMC Cancer; 2024 Apr; 24(1):458. PubMed ID: 38609917
[TBL] [Abstract] [Full Text] [Related]
7. Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study.
Py C; De Vito C; Tsantoulis P; Kaya G; Labidi-Galy SI; Dietrich PY
Swiss Med Wkly; 2023 Dec; 153():3504. PubMed ID: 38579317
[TBL] [Abstract] [Full Text] [Related]
8. Divergent local and systemic antitumor response in primary uveal melanomas.
Lucibello F; Lalanne AI; Le Gac AL; Soumare A; Aflaki S; Cyrta J; Dubreuil L; Mestdagh M; Salou M; Houy A; Ekwegbara C; Jamet C; Gardrat S; Le Ven A; Bernardeau K; Cassoux N; Matet A; Malaise D; Pierron G; Piperno-Neumann S; Stern MH; Rodrigues M; Lantz O
J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38563818
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
[TBL] [Abstract] [Full Text] [Related]
10. Case report: A case of Paget disease outside the axillary breast.
Zhou Z; Zhou B; Wu X; Wei W
Medicine (Baltimore); 2024 Mar; 103(13):e37541. PubMed ID: 38552095
[TBL] [Abstract] [Full Text] [Related]
11. Trauma plays an important role in acral melanoma: A retrospective study of 303 patients.
Huang R; Zhao M; Zhang G; Yang Y; Wang J; Zheng K; Li L; Su X; Zhao L; Wu Y; Zou Z
Cancer Med; 2024 Apr; 13(7):e7137. PubMed ID: 38545846
[TBL] [Abstract] [Full Text] [Related]
12. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract] [Full Text] [Related]
13. Malignancy After Living Donor Liver Transplantation.
Kobayashi T; Miura K; Ishikawa H; Sakata J; Takizawa K; Hirose Y; Toge K; Saito S; Abe S; Kawachi Y; Ichikawa H; Shimada Y; Takahashi Y; Wakai T; Kinoshita Y
Transplant Proc; 2024 Apr; 56(3):660-666. PubMed ID: 38519268
[TBL] [Abstract] [Full Text] [Related]
14. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.
Su DG; Schoenfeld DA; Ibrahim W; Cabrejo R; Djureinovic D; Baumann R; Rimm DL; Khan SA; Halaban R; Kluger HM; Olino K; Galan A; Clune J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519058
[TBL] [Abstract] [Full Text] [Related]
15. Twelve years after: The french national network on rare head and neck tumours (REFCOR).
Gasne C; Atallah S; Dauzier E; Thariat J; Fakhry N; Verillaud B; Classe M; Vergez S; Moya-Plana A; Costes-Martineau V; Righini C; de Gabory L; Digue L; Dupin C; Ferrand FR; Even C; Baujat B;
Oral Oncol; 2024 Apr; 151():106762. PubMed ID: 38513311
[TBL] [Abstract] [Full Text] [Related]
16. The role of GAPDH in the selective toxicity of CNP in melanoma cells.
von Montfort C; Aplak E; Ebbert L; Wenzel CK; Klahm NP; Stahl W; Brenneisen P
PLoS One; 2024; 19(3):e0300718. PubMed ID: 38512909
[TBL] [Abstract] [Full Text] [Related]
17. Endoscopic mastectomy followed by immediate breast reconstruction with fat grafting for breast cancer.
Narui K; Satake T; Ishikawa T; Muto M; Tsunoda Y; Yamada A; Kawashima K; Uenaka N; Fujiwara Y; Oshi M; Adachi S; Suzuki C; Wada T; Yamamoto S; Tanabe M; Maegawa J; Endo I
Breast Cancer; 2024 May; 31(3):476-484. PubMed ID: 38512534
[TBL] [Abstract] [Full Text] [Related]
18. VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives.
Malekan M; Haass NK; Rokni GR; Gholizadeh N; Ebrahimzadeh MA; Kazeminejad A
Life Sci; 2024 May; 345():122563. PubMed ID: 38508233
[TBL] [Abstract] [Full Text] [Related]
19. Effects of COVID-19 Pandemic on the Diagnosis of Melanoma and Keratinocyte Carcinomas: a Systematic Review and Meta-analysis.
Díaz-Calvillo P; Muñoz-Barba D; Ureña-Paniego C; Maul LV; Cerminara S; Kostner L; Martínez López A; Arias-Santiago S
Acta Derm Venereol; 2024 Mar; 104():adv19460. PubMed ID: 38483083
[TBL] [Abstract] [Full Text] [Related]
20. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract] [Full Text] [Related]
[Next]
